FDA Grants Full Approval to Blinatumomab for MRD+ B-cell Pre

The FDA has granted regular approval to blinatumomab (Blincyto) for the treatment of adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease of at least 0.1%

Related Keywords

Philadelphia , Pennsylvania , United States , Germany , Davidm Reese , , Amgen , Accessed June , Blinatumomab , Blincyto , Nmrd , Minimal Residual Disease , B Cell Precursor Acute Lymphoblastic Leukemia , Wall , Leukemia , Blood Cancer , Fda , Fda Approval , Regular Approval , Mlb All ,